Achondroplasia Trial Shows Growth Gains in Children

Achondroplasia, which affects roughly one in every 26,000 to 40,000 children, stems from genetic changes that trigger overactivity in the FGFR3 pathway, effectively inhibiting bone development. By acting as a selective FGFR1–3 inhibitor, the once-daily medication helps modulate these signals to encourage natural growth. Researchers observed these height improvements over a 52-week period, with notable gains in body proportionality among children aged 3 to 8.

Children's Hospital Colorado served as one of 27 international sites for the study, which was sponsored by BridgeBio Pharma. Dr. Klane White, a co-author of the study, noted that while height was the primary metric, the findings suggest a broader potential to improve the daily health of patients who often face complications involving their spine and limbs. While the initial safety profile showed only mild to moderate side effects, the research team is now transitioning participants into a long-term study to monitor physical function and quality of life outcomes.